Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions
The purpose of this narrative review is to describe the current use environment of both natural and synthetic cannabinoids while providing context for cannabinoid chemistry and pharmacology. In addition to a long history of recreational and nonmedical use, natural cannabinoids are increasingly used...
Gespeichert in:
Veröffentlicht in: | Journal of clinical pharmacology 2021-08, Vol.61 (S2), p.S37-S52 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | S52 |
---|---|
container_issue | S2 |
container_start_page | S37 |
container_title | Journal of clinical pharmacology |
container_volume | 61 |
creator | Brown, Joshua D. Rivera Rivera, Kevin J. Hernandez, Leilanie Y. Crespo Doenges, Matthew R. Auchey, India Pham, Thanh Goodin, Amie J. |
description | The purpose of this narrative review is to describe the current use environment of both natural and synthetic cannabinoids while providing context for cannabinoid chemistry and pharmacology. In addition to a long history of recreational and nonmedical use, natural cannabinoids are increasingly used as prescription products, through medical cannabis programs, and as consumer health products. Despite anecdotal safety evidence, cannabis and cannabinoids are pharmacologically complex and pose risks for adverse drug events and drug‐drug interactions. Synthetic cannabinoids, particularly agonists of cannabinoid receptors, are more potent than natural cannabinoids and can lead to more severe reactions and medical emergencies. This review provides a summary of approved uses and an overview of mechanisms of action for adverse drug events with natural and synthetic cannabinoids. Clinical considerations for special populations that may be at heightened risk for drug‐drug interactions and adverse drug events while using natural or synthetic cannabinoids are examined, and recommendations are provided. |
doi_str_mv | 10.1002/jcph.1871 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_wiley_primary_10_1002_jcph_1871_JCPH1871</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2561347345</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-39411ffa4f234850fc18c3c8a659039c9d9bd173edaf5b2d887cb97a0cc4beb23</originalsourceid><addsrcrecordid>eNp1kEFLwzAYhoMobk4P_gEpeFFYt6RJ2sTbqNNNhg5055Km6dbRpTNpJ_33ttv0IHj64OXh4eMB4BrBAYLQG67ldjVALEAnoIso9VziQ3IKuhBy5HoBhB1wYe0aQuQTis5BBxPMfUpZF8SvoqyMyB2hE-e91uVKlZl0QqG1iDNdZIl9cOYrYTZCFnmxrPvOwirbd0bJThmrnEdTLZ3xTumyGVvJfpjqUhkhy6zQ9hKcpSK36up4e2DxNP4IJ-7s7XkajmauxIwhF3OCUJoKknqYMApTiZjEkgmfcoi55AmPExRglYiUxl7CWCBjHggoJYlV7OEeuDt4t6b4rJQto01mpcpzoVVR2cijPuJeU4A16O0fdF1URjff7SlMAkxoQ90fKGkKa41Ko63JNsLUEYJRGz5qw0dt-Ia9ORqreKOSX_KndAMMD8BXlqv6f1P0Es4ne-U3j4eMrQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2561347345</pqid></control><display><type>article</type><title>Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Brown, Joshua D. ; Rivera Rivera, Kevin J. ; Hernandez, Leilanie Y. Crespo ; Doenges, Matthew R. ; Auchey, India ; Pham, Thanh ; Goodin, Amie J.</creator><creatorcontrib>Brown, Joshua D. ; Rivera Rivera, Kevin J. ; Hernandez, Leilanie Y. Crespo ; Doenges, Matthew R. ; Auchey, India ; Pham, Thanh ; Goodin, Amie J.</creatorcontrib><description>The purpose of this narrative review is to describe the current use environment of both natural and synthetic cannabinoids while providing context for cannabinoid chemistry and pharmacology. In addition to a long history of recreational and nonmedical use, natural cannabinoids are increasingly used as prescription products, through medical cannabis programs, and as consumer health products. Despite anecdotal safety evidence, cannabis and cannabinoids are pharmacologically complex and pose risks for adverse drug events and drug‐drug interactions. Synthetic cannabinoids, particularly agonists of cannabinoid receptors, are more potent than natural cannabinoids and can lead to more severe reactions and medical emergencies. This review provides a summary of approved uses and an overview of mechanisms of action for adverse drug events with natural and synthetic cannabinoids. Clinical considerations for special populations that may be at heightened risk for drug‐drug interactions and adverse drug events while using natural or synthetic cannabinoids are examined, and recommendations are provided.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1002/jcph.1871</identifier><identifier>PMID: 34396558</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>adverse drug events ; Age Factors ; cannabinoid pharmacology ; Cannabinoid Receptor Agonists - metabolism ; Cannabinoid receptors ; cannabinoids ; Cannabinoids - adverse effects ; Cannabinoids - chemistry ; Cannabinoids - pharmacology ; Cannabis ; Drug and Narcotic Control - organization & administration ; Drug Interactions ; drug‐drug interactions ; Endocannabinoids - metabolism ; Female ; Humans ; Medical Marijuana - pharmacology ; Medical Marijuana - therapeutic use ; Pharmacists ; Pregnancy ; Prenatal Exposure Delayed Effects - epidemiology ; Prenatal Exposure Delayed Effects - pathology ; synthetic cannabinoids ; United States</subject><ispartof>Journal of clinical pharmacology, 2021-08, Vol.61 (S2), p.S37-S52</ispartof><rights>2021, The American College of Clinical Pharmacology</rights><rights>2021, The American College of Clinical Pharmacology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-39411ffa4f234850fc18c3c8a659039c9d9bd173edaf5b2d887cb97a0cc4beb23</citedby><cites>FETCH-LOGICAL-c3881-39411ffa4f234850fc18c3c8a659039c9d9bd173edaf5b2d887cb97a0cc4beb23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcph.1871$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcph.1871$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27926,27927,45576,45577</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34396558$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brown, Joshua D.</creatorcontrib><creatorcontrib>Rivera Rivera, Kevin J.</creatorcontrib><creatorcontrib>Hernandez, Leilanie Y. Crespo</creatorcontrib><creatorcontrib>Doenges, Matthew R.</creatorcontrib><creatorcontrib>Auchey, India</creatorcontrib><creatorcontrib>Pham, Thanh</creatorcontrib><creatorcontrib>Goodin, Amie J.</creatorcontrib><title>Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>The purpose of this narrative review is to describe the current use environment of both natural and synthetic cannabinoids while providing context for cannabinoid chemistry and pharmacology. In addition to a long history of recreational and nonmedical use, natural cannabinoids are increasingly used as prescription products, through medical cannabis programs, and as consumer health products. Despite anecdotal safety evidence, cannabis and cannabinoids are pharmacologically complex and pose risks for adverse drug events and drug‐drug interactions. Synthetic cannabinoids, particularly agonists of cannabinoid receptors, are more potent than natural cannabinoids and can lead to more severe reactions and medical emergencies. This review provides a summary of approved uses and an overview of mechanisms of action for adverse drug events with natural and synthetic cannabinoids. Clinical considerations for special populations that may be at heightened risk for drug‐drug interactions and adverse drug events while using natural or synthetic cannabinoids are examined, and recommendations are provided.</description><subject>adverse drug events</subject><subject>Age Factors</subject><subject>cannabinoid pharmacology</subject><subject>Cannabinoid Receptor Agonists - metabolism</subject><subject>Cannabinoid receptors</subject><subject>cannabinoids</subject><subject>Cannabinoids - adverse effects</subject><subject>Cannabinoids - chemistry</subject><subject>Cannabinoids - pharmacology</subject><subject>Cannabis</subject><subject>Drug and Narcotic Control - organization & administration</subject><subject>Drug Interactions</subject><subject>drug‐drug interactions</subject><subject>Endocannabinoids - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Medical Marijuana - pharmacology</subject><subject>Medical Marijuana - therapeutic use</subject><subject>Pharmacists</subject><subject>Pregnancy</subject><subject>Prenatal Exposure Delayed Effects - epidemiology</subject><subject>Prenatal Exposure Delayed Effects - pathology</subject><subject>synthetic cannabinoids</subject><subject>United States</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEFLwzAYhoMobk4P_gEpeFFYt6RJ2sTbqNNNhg5055Km6dbRpTNpJ_33ttv0IHj64OXh4eMB4BrBAYLQG67ldjVALEAnoIso9VziQ3IKuhBy5HoBhB1wYe0aQuQTis5BBxPMfUpZF8SvoqyMyB2hE-e91uVKlZl0QqG1iDNdZIl9cOYrYTZCFnmxrPvOwirbd0bJThmrnEdTLZ3xTumyGVvJfpjqUhkhy6zQ9hKcpSK36up4e2DxNP4IJ-7s7XkajmauxIwhF3OCUJoKknqYMApTiZjEkgmfcoi55AmPExRglYiUxl7CWCBjHggoJYlV7OEeuDt4t6b4rJQto01mpcpzoVVR2cijPuJeU4A16O0fdF1URjff7SlMAkxoQ90fKGkKa41Ko63JNsLUEYJRGz5qw0dt-Ia9ORqreKOSX_KndAMMD8BXlqv6f1P0Es4ne-U3j4eMrQ</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Brown, Joshua D.</creator><creator>Rivera Rivera, Kevin J.</creator><creator>Hernandez, Leilanie Y. Crespo</creator><creator>Doenges, Matthew R.</creator><creator>Auchey, India</creator><creator>Pham, Thanh</creator><creator>Goodin, Amie J.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>202108</creationdate><title>Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions</title><author>Brown, Joshua D. ; Rivera Rivera, Kevin J. ; Hernandez, Leilanie Y. Crespo ; Doenges, Matthew R. ; Auchey, India ; Pham, Thanh ; Goodin, Amie J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-39411ffa4f234850fc18c3c8a659039c9d9bd173edaf5b2d887cb97a0cc4beb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>adverse drug events</topic><topic>Age Factors</topic><topic>cannabinoid pharmacology</topic><topic>Cannabinoid Receptor Agonists - metabolism</topic><topic>Cannabinoid receptors</topic><topic>cannabinoids</topic><topic>Cannabinoids - adverse effects</topic><topic>Cannabinoids - chemistry</topic><topic>Cannabinoids - pharmacology</topic><topic>Cannabis</topic><topic>Drug and Narcotic Control - organization & administration</topic><topic>Drug Interactions</topic><topic>drug‐drug interactions</topic><topic>Endocannabinoids - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Medical Marijuana - pharmacology</topic><topic>Medical Marijuana - therapeutic use</topic><topic>Pharmacists</topic><topic>Pregnancy</topic><topic>Prenatal Exposure Delayed Effects - epidemiology</topic><topic>Prenatal Exposure Delayed Effects - pathology</topic><topic>synthetic cannabinoids</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brown, Joshua D.</creatorcontrib><creatorcontrib>Rivera Rivera, Kevin J.</creatorcontrib><creatorcontrib>Hernandez, Leilanie Y. Crespo</creatorcontrib><creatorcontrib>Doenges, Matthew R.</creatorcontrib><creatorcontrib>Auchey, India</creatorcontrib><creatorcontrib>Pham, Thanh</creatorcontrib><creatorcontrib>Goodin, Amie J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brown, Joshua D.</au><au>Rivera Rivera, Kevin J.</au><au>Hernandez, Leilanie Y. Crespo</au><au>Doenges, Matthew R.</au><au>Auchey, India</au><au>Pham, Thanh</au><au>Goodin, Amie J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>2021-08</date><risdate>2021</risdate><volume>61</volume><issue>S2</issue><spage>S37</spage><epage>S52</epage><pages>S37-S52</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><abstract>The purpose of this narrative review is to describe the current use environment of both natural and synthetic cannabinoids while providing context for cannabinoid chemistry and pharmacology. In addition to a long history of recreational and nonmedical use, natural cannabinoids are increasingly used as prescription products, through medical cannabis programs, and as consumer health products. Despite anecdotal safety evidence, cannabis and cannabinoids are pharmacologically complex and pose risks for adverse drug events and drug‐drug interactions. Synthetic cannabinoids, particularly agonists of cannabinoid receptors, are more potent than natural cannabinoids and can lead to more severe reactions and medical emergencies. This review provides a summary of approved uses and an overview of mechanisms of action for adverse drug events with natural and synthetic cannabinoids. Clinical considerations for special populations that may be at heightened risk for drug‐drug interactions and adverse drug events while using natural or synthetic cannabinoids are examined, and recommendations are provided.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34396558</pmid><doi>10.1002/jcph.1871</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0091-2700 |
ispartof | Journal of clinical pharmacology, 2021-08, Vol.61 (S2), p.S37-S52 |
issn | 0091-2700 1552-4604 |
language | eng |
recordid | cdi_wiley_primary_10_1002_jcph_1871_JCPH1871 |
source | MEDLINE; Access via Wiley Online Library |
subjects | adverse drug events Age Factors cannabinoid pharmacology Cannabinoid Receptor Agonists - metabolism Cannabinoid receptors cannabinoids Cannabinoids - adverse effects Cannabinoids - chemistry Cannabinoids - pharmacology Cannabis Drug and Narcotic Control - organization & administration Drug Interactions drug‐drug interactions Endocannabinoids - metabolism Female Humans Medical Marijuana - pharmacology Medical Marijuana - therapeutic use Pharmacists Pregnancy Prenatal Exposure Delayed Effects - epidemiology Prenatal Exposure Delayed Effects - pathology synthetic cannabinoids United States |
title | Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T01%3A23%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Natural%20and%20Synthetic%20Cannabinoids:%20Pharmacology,%20Uses,%20Adverse%20Drug%20Events,%20and%20Drug%20Interactions&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Brown,%20Joshua%20D.&rft.date=2021-08&rft.volume=61&rft.issue=S2&rft.spage=S37&rft.epage=S52&rft.pages=S37-S52&rft.issn=0091-2700&rft.eissn=1552-4604&rft_id=info:doi/10.1002/jcph.1871&rft_dat=%3Cproquest_cross%3E2561347345%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2561347345&rft_id=info:pmid/34396558&rfr_iscdi=true |